News
ENDPQ
0.0006
NaN%
--
Endo International reports Q1 results; initiates FY24 outlook
Endo International reports Q1 results; initiates FY24 outlook May 31, 2024. Endo had $641 million in unrestricted cash and cash equivalents as of March 31, 2023. The company is providing financial guidance for the full-year ending December 31, 2025.
Seeking Alpha · 05/31 08:33
Endo hit with $1.5B in fines, forfeiture related to distribution of opioid Opana
Healthcare Endo hit with $1.5B in fines, forfeiture related to distribution of opioid Opana. DoJ: Endo pleaded guilty to a misdemeanor count of introducing misbranded drugs into interstate commerce. Endo Health Solutions will not emerge from bankruptcy. The company was hit with criminal fines related to its distribution of the opioid drug Opana ER.
Seeking Alpha · 05/03 17:24
Weekly Report: what happened at ENDPQ last week (0422-0426)?
Weekly Report · 04/29 09:42
Weekly Report: what happened at ENDPQ last week (0415-0419)?
Weekly Report · 04/22 09:40
Weekly Report: what happened at ENDPQ last week (0408-0412)?
Weekly Report · 04/15 09:36
Weekly Report: what happened at ENDPQ last week (0401-0405)?
Weekly Report · 04/08 09:38
Weekly Report: what happened at ENDPQ last week (0325-0329)?
Weekly Report · 04/01 09:38
Weekly Report: what happened at ENDPQ last week (0318-0322)?
Weekly Report · 03/25 09:39
Endo gains OK for Chapter 11 bankruptcy reorgaanization
Healthcare Endo gains OK for Chapter 11 bankruptcy reorgaanization. Nearly all of the company's assets are being sold to a new entity. The transaction could close as early as April. A federal bankruptcy court has authorized Endo International's bankruptcy reorganization plan.
Seeking Alpha · 03/19 22:31
Weekly Report: what happened at ENDPQ last week (0311-0315)?
Weekly Report · 03/18 09:38
Weekly Report: what happened at ENDPQ last week (0304-0308)?
Weekly Report · 03/11 09:38
Weekly Report: what happened at ENDPQ last week (0226-0301)?
Weekly Report · 03/04 09:39
Endo to pay over $1.45B to feds to settle misbranding opioid charge
Endo to pay over $1.45B to feds to settle misbranding opioid charge related to the opioid Opana ER. The Justice Department said the total marks the second-highest criminal penalties ever made against a drug company. Endo will also be responsible for another $450M in criminal forfeiture.
Seeking Alpha · 02/29 18:46
Press Release: Opioid Manufacturer Endo Health -2-
Endo's proposed sale of assets contravened key requirements of the Bankruptcy Code. The government objected to Endo's plan to sell its assets in a way that would have avoided paying creditors. The federal government asserted claims in the bankruptcy proceeding against Endo. Endo is accused of misbranding Opana ER and other opioids.
Dow Jones · 02/29 16:31
Press Release: Opioid Manufacturer Endo Health Solutions Inc. Agrees to Global Resolution of Criminal and Civil Investigations into Sales and Marketing of Branded Opioid Drug
Endo Health Solutions Inc. Agrees to resolve criminal and civil investigations into sales and marketing of the opioid drug Opana ER with INTAC. The United States also reaches settlement with Endo International in Endo's bankruptcy case to settle its monetary claims. The government will be paid up to $464.9 million over 10 years. The criminal resolution includes the second-largest financial penalties ever levied against a pharmaceutical company.
Dow Jones · 02/29 16:31
*DOJ: Endo Health Solutions Agrees to Civil Settlement of $475.6 Million
Dow Jones · 02/29 16:29
*DOJ: Endo Health Solutions Agrees to Plead Guilty in Federal Court to One-Count Misdemeanor Information
Dow Jones · 02/29 16:29
*DOJ: U.S. to Get Up to $464.9 Million Over 10 Years Under Endo Bankruptcy Agreement
Dow Jones · 02/29 16:27
*DOJ: U.S. Also Reaches Settlement with Endo International in Bankruptcy Case
Dow Jones · 02/29 16:25
Weekly Report: what happened at ENDPQ last week (0219-0223)?
Weekly Report · 02/26 09:42
More
Webull provides a variety of real-time ENDPQ stock news. You can receive the latest news about Endo Intl Plc through multiple platforms. This information may help you make smarter investment decisions.
About ENDPQ
Endo International plc is a specialty pharmaceutical company. The Company operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL, EDEX and LIDODERM, among others. Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection. The Company's Generic Pharmaceuticals segment consists of a product portfolio, including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic and sprays.